A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A
Administered By
Awarded By
Contributors
- Beerman, Rebecca Clinical Data Manager
- Montefiori, David Charles Principal Investigator
- Sarzotti-Kelsoe, Marcella Director
- Shen, Xiaoying Co Investigator
Start/End
- May 1, 2021 - June 30, 2022